Dr. O'Connor on Recent FDA Approvals in MCL

Owen O'Connor
Published: Wednesday, Nov 15, 2017



Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).

One of the big advances in the field was recognizing that MCL is not one disease. The proliferative rate is an important determinant for many patients.

Bortezomib (Velcade) was the first drug approved for MCL, explains O'Connor. Over the years, the approval of proteasome inhibitors, such as acalabrutinib, broadened the portfolio of available agents. Acalabrutinib is felt to be a more selective BTK inhibitor, explains O'Connor.


Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the recent FDA approval of acalabrutinib (Calquence) for patients with mantle cell lymphoma (MCL).

One of the big advances in the field was recognizing that MCL is not one disease. The proliferative rate is an important determinant for many patients.

Bortezomib (Velcade) was the first drug approved for MCL, explains O'Connor. Over the years, the approval of proteasome inhibitors, such as acalabrutinib, broadened the portfolio of available agents. Acalabrutinib is felt to be a more selective BTK inhibitor, explains O'Connor.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x